Fig. 9.

p38 MAPK phosphorylation is decreased by treatment with the p38 MAPK inhibitor SB203580 in differentiating myogenic progenitors. (A) Western blotting of whole cell lysates treated with SB203580 was performed to analyze activation of p38 MAPK during differentiation of wild-type or emerin-null progenitors. DMSO treatment was the control. Three biological replicates are shown for each treatment. (B) Densitometry was performed and phosphorylated p38 MAPK was normalized to total p38 MAPK protein in each sample. Levels of phosphorylated p38 MAPK for each condition were normalized to DMSO-treated wild-type cells. Results are mean±s.d. of n=3 for each condition; *P<0.05, **P<0.01 using unpaired, two-tailed t-tests.